Reporting
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
Learn MoreEnrolling
The role of fatty liver in the epidemic of advanced chronic liver disease among people living with HIV
Learn MoreStart-up
Development and validation of an anal cancer screening algorithm in HIV-positive men who have sex with men
Learn MoreReporting
Immunogenicity outcomes in people living with HIV following vaccination for COVID-19 (HIV-COV)
Learn MoreOngoing
The impact of COVID-19 on persons with HIV in Canada: Data from the HIV/HCV co-infection/CCC (CTN 222) and HIV aging cohorts (CTN 314)
Learn MoreEnrolling
A multicenter, randomized controlled trial of the efficacy, safety and immunogenicity of the 9-valent human papillomavirus (HPV) vaccination in preventing recurrence of high-grade anal dysplasia in HIV-positive men who have sex with men (MSM)
Learn MoreCompleted
BonE health in ageING Women: improvement or prevention of changes in bone mineral density by switching antiretroviral agents
Learn MoreOngoing
Efficacy potential of an internet-based sleep program to improve sleep quality in people with HIV
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
